aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. USO
2. SPY
3. AMZN
4. GNK
5. FLUT
6. TMUS
7. AVGO
8. KRUS
9. MTZ
10. BKR

Go back to aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs

aTyr Pharma (LIFE) Tops Q2 EPS by 4c

August 13, 2020 4:04 PM EDT

aTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.69), $0.04 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $189 thousand versus the consensus estimate of $400 thousand.

While the advent of the global COVID-19 pandemic impacted our Phase 1b/2a clinical trial of ATYR1923 in... More